WOLF Deep Coverage Review — Analysis as of July 23, 2026
Wolfspeed’s restructuring created time, but margin, utilization and contracted demand must improve together before the equity thesis can recover.
Market Outlooks
JQC Research Note — Income Meets Fragile Coverage
JQC’s discounted floating-rate income faces weak distribution coverage, heavy leverage and sensitivity to rates, credit and net asset value.
JQC Deep Coverage Review — Analysis as of July 23, 2026
JQC’s discounted floating-rate income faces fragile distribution coverage, heavy leverage and a concentrated policy-and-credit evidence window.
PLTR Research Note — Growth Meets a High Bar
PLTR’s commercial AI momentum faces a high August evidence bar as valuation sensitivity, insider supply and weak sector breadth complicate the setup.
PLTR Deep Coverage Review — Analysis as of July 23, 2026
PLTR’s AI growth remains compelling, but August results must justify a demanding valuation amid weak technology-sector sponsorship and insider supply.
HBAN Research Note — Margin Recovery Meets Credit
HBAN’s improving setup still depends on net interest margin, deposit costs and credit evidence after a strong three-week share-price advance.
HBAN Deep Coverage Review — Analysis as of July 23, 2026
HBAN’s margin recovery case depends on steadier deposit costs, sound credit and Q2 evidence strong enough to justify its recent share-price advance.
VGM Research Note — Income Meets Leverage
VGM’s high tax-exempt distribution meets 36.52% effective leverage and a market price that now stands above the fund’s underlying net asset value.
VGM Deep Coverage Review — Analysis as of July 23, 2026
VGM’s tax-exempt income remains attractive, while leverage and a premium to net asset value leave less room for rate or coverage disappointment.
Desk Note — Retatrutide Advances Toward Filing · Jul 23
Two more Phase 3 retatrutide successes and a Q1 2027 filing plan strengthen LLY’s pipeline case while key safety and valuation questions remain.